SHANGHAI, June 29 (Reuters) – Pfizer’s ecnoglutide and Innovent Biologics’ mazdutide have passed a preliminary review to be potentially included in China’s basic medical insurance drug catalogue, a list published by the National Healthcare Security Administration showed on Monday.
The two drugs, which belong to the class of GLP-1 receptor agonist drugs, are both approved in China as treatments for weight management and type II diabetes.
A spokesperson for Pfizer did not immediately respond to a request for comment.
A spokesperson for Innovent told Reuters that in terms of medical insurance coverage in China only treatment for diabetes could be considered.
(Reporting by Andrew Silver; Additional reporting by Ethan Wang and Ryan Woo; Editing by Clarence Fernandez and Tom Hogue)
Comments